ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 6, 2024 -- Autologous hematopoietic cell transplant (auto-HCT) is not beneficial for patients with mantle cell lymphoma (MCL) in first complete remission (CR) with undetectable minimal residual disease (uMRD), according to a study to be presented at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.
Timothy S. Fenske, M.D., from the Medical College of Wisconsin in Milwaukee, and colleagues conducted a four-arm trial involving patients with MCL between 18 and 70 years of age and in first remission. Patients in CR with uMRD at 1 in 10-6 sensitivity (uMRD6) were randomly assigned to arm A (auto-HCT + three years of maintenance rituximab [MR]) or arm B (three years of MR alone). Patients with MRD-positive CR or MRD-indeterminate CR both received auto-HCT + three years of MR (arms C and D, respectively). The primary end point was to compare survival in arms A and B.
From August 2017 to July 2024, 257, 259, 49, and 85 patients were enrolled in arms A, B, C, and D, respectively. The researchers found that the estimated overall survival hazard ratios for arms A and B in all randomized and treated-as-assigned patients (516 and 375, respectively) were 1.11 (95 percent confidence interval, 0.71 to 1.74; P = 0.66) and 1.00 (95 percent confidence interval, 0.58 to 1.74; P = 0.99), and crossed the boundary for futility. Three-year overall survival was 82.1 and 82.7 percent, respectively, for arms A and B in all randomly assigned patients, and 86.2 and 84.8 percent, respectively, in those treated as assigned.
"In this interim analysis, in the era of highly effective induction and maintenance regimens, MCL patients in first CR with uMRD6 did not benefit from consolidative auto-HCT," the authors write.
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
AI Improves Risk Prediction in Patients With Myelofibrosis Undergoing Allo-HCT
FRIDAY, April 4, 2025 -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) enhances risk stratification...
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
FRIDAY, March 7, 2025 -- Tattooed individuals have an increased risk for lymphoma and skin cancers, according to a study recently published in BMC Public Health. Signe Bedsted...
Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival
MONDAY, Jan. 13, 2025 -- Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.